Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I–III clinical trials

AIMS/INTRODUCTION: We investigated the safety and tolerability of empagliflozin (EMPA) in East Asian patients with type 2 diabetes. MATERIALS AND METHODS: Data were pooled from participants with type 2 diabetes evenly randomized to a placebo, EMPA 10 mg or EMPA 25 mg in 15 phase I–III trials. Advers...

Descripción completa

Detalles Bibliográficos
Autores principales: Yabe, Daisuke, Yasui, Atsutaka, Ji, Linong, Lee, Moon‐Kyu, Ma, Ronald Ching Wan, Chang, Tien‐Jyun, Okamura, Tomoo, Zeller, Cordula, Kaspers, Stefan, Lee, Jisoo, Kohler, Sven, Seino, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400242/
https://www.ncbi.nlm.nih.gov/pubmed/30099847
http://dx.doi.org/10.1111/jdi.12910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400242/
https://www.ncbi.nlm.nih.gov/pubmed/30099847
http://dx.doi.org/10.1111/jdi.12910

Ejemplares similares